Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP

Cell Metabolism

Volumn 24, Issue 6, 2016, Pages 863-874

  Papazyan, Romeo ^a   Sun, Zheng ^a,b   Kim, Yong Hoon ^a   Titchenell, Paul M ^a   Hill, David A ^a   Lu, Wenyun ^c   Damle, Manashree ^a   Wan, Min ^a   Zhang, Yuxiang ^a   Briggs, Erika R ^a   Rabinowitz, Joshua D ^c   Lazar, Mitchell A ^a  

^a Institute for Diabetes   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; HISTONE DEACETYLASE 3; SREBP CLEAVAGE ACTIVATING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FATTY ACID; GLUCOSE; HISTONE DEACETYLASE; LIPID; PROTEIN BINDING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; ECTOPIC EXPRESSION; FATTY ACID OXIDATION; INFLAMMATION; LETHALITY; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; LIVER CELL; LIVER INJURY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FATTY LIVER; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; BASE SEQUENCE; FATTY ACIDS; FATTY LIVER; GLUCOSE; HISTONE DEACETYLASES; INFLAMMATION; LIPIDS; LIPOGENESIS; LIVER; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN BINDING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 85003838990     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.10.012     Document Type: Article

References (51)

1. Alkhouri, N., Dixon, L.J., Feldstein, A.E., Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3 (2009), 445–451.
2. Arrese, M., Cabrera, D., Kalergis, A.M., Feldstein, A.E., Innate immunity and inflammation in NAFLD/NASH. Dig. Dis. Sci. 61 (2016), 1294–1303.
3. Benhamed, F., Denechaud, P.D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 122 (2012), 2176–2194.
4. Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004), 147–152.
5. Cazanave, S.C., Mott, J.L., Elmi, N.A., Bronk, S.F., Werneburg, N.W., Akazawa, Y., Kahraman, A., Garrison, S.P., Zambetti, G.P., Charlton, M.R., Gores, G.J., JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J. Biol. Chem. 284 (2009), 26591–26602.
6. Cotter, D.G., Ercal, B., Huang, X., Leid, J.M., d'Avignon, D.A., Graham, M.J., Dietzen, D.J., Brunt, E.M., Patti, G.J., Crawford, P.A., Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J. Clin. Invest. 124 (2014), 5175–5190.
7. Day, C.P., James, O.F.W., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
8. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
9. Duarte, J.A.G., Carvalho, F., Pearson, M., Horton, J.D., Browning, J.D., Jones, J.G., Burgess, S.C., A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice. J. Lipid Res. 55 (2014), 2541–2553.
10. Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S.E., Alenghat, T., Liu, X.S., Lazar, M.A., A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331 (2011), 1315–1319.
11. Fon Tacer, K., Rozman, D., Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipids, 2011, 2011, 783976.
12. Fromenty, B., Pessayre, D., Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67 (1995), 101–154.
13. Gilardi, F., Migliavacca, E., Naldi, A., Baruchet, M., Canella, D., Le Martelot, G., Guex, N., Desvergne, B., CycliX Consortium. Genome-wide analysis of SREBP1 activity around the clock reveals its combined dependency on nutrient and circadian signals. PLoS Genet., 10, 2014, e1004155.
14. Gooley, J.J., Chua, E.C., Diurnal regulation of lipid metabolism and applications of circadian lipidomics. J. Genet. Genomics 41 (2014), 231–250.
15. Guéraud, F., Atalay, M., Bresgen, N., Cipak, A., Eckl, P.M., Huc, L., Jouanin, I., Siems, W., Uchida, K., Chemistry and biochemistry of lipid peroxidation products. Free Radic. Res. 44 (2010), 1098–1124.
16. Hems, D.A., Rath, E.A., Verrinder, T.R., Fatty acid synthesis in liver and adipose tissue of normal and genetically obese (ob/ob) mice during the 24-hour cycle. Biochem. J. 150 (1975), 167–173.
17. Hori, T., Chen, F., Baine, A.M.T., Gardner, L.B., Nguyen, J.H., Fulminant liver failure model with hepatic encephalopathy in the mouse. Ann. Gastroenterol. 24 (2011), 294–306.
18. Horton, J.D., Bashmakov, Y., Shimomura, I., Shimano, H., Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA 95 (1998), 5987–5992.
19. Horton, J.D., Shimomura, I., Brown, M.S., Hammer, R.E., Goldstein, J.L., Shimano, H., Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Invest. 101 (1998), 2331–2339.
20. Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109 (2002), 1125–1131.
21. Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, S.W., Brown, M.S., Goldstein, J.L., Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100 (2003), 12027–12032.
22. Kang, H.M., Ahn, S.H., Choi, P., Ko, Y.A., Han, S.H., Chinga, F., Park, A.S.D., Tao, J., Sharma, K., Pullman, J., et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21 (2015), 37–46.
23. Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J.W., Fernandez, A.M., Reitman, M.L., Yakar, S., Stannard, B., Heron-Milhavet, L., et al. Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52 (2003), 1770–1778.
24. Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W.T., et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21 (2015), 739–746.
25. Lam, B., Younossi, Z.M., Treatment options for nonalcoholic fatty liver disease. Therap. Adv. Gastroenterol. 3 (2010), 121–137.
26. Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Parks, E.J., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 (2014), 726–735.
27. Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., Birnbaum, M.J., Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 10 (2009), 405–418.
28. Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V. Jr., Ory, D.S., Schaffer, J.E., Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. USA 100 (2003), 3077–3082.
29. Matsuda, M., Korn, B.S., Hammer, R.E., Moon, Y.A., Komuro, R., Horton, J.D., Goldstein, J.L., Brown, M.S., Shimomura, I., SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15 (2001), 1206–1216.
30. Mittal, M., Siddiqui, M.R., Tran, K., Reddy, S.P., Malik, A.B., Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 20 (2014), 1126–1167.
31. Monetti, M., Levin, M.C., Watt, M.J., Sajan, M.P., Marmor, S., Hubbard, B.K., Stevens, R.D., Bain, J.R., Newgard, C.B., Farese, R.V. Sr., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6 (2007), 69–78.
32. Moon, Y.A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Brown, M.S., Goldstein, J.L., Horton, J.D., The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15 (2012), 240–246.
33. Moore, D.D., Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab. 15 (2012), 615–622.
34. Musso, G., Cassader, M., Gambino, R., Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15 (2016), 249–274.
35. Neuschwander-Tetri, B.A., Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep. 12 (2010), 49–56.
36. Neuschwander-Tetri, B.A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52 (2010), 774–788.
37. Sahebkar, A., Chew, G.T., Watts, G.F., New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 15 (2014), 493–503.
38. Shimano, H., Horton, J.D., Hammer, R.E., Shimomura, I., Brown, M.S., Goldstein, J.L., Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98 (1996), 1575–1584.
39. Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., Goldstein, J.L., Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 99 (1997), 846–854.
40. Snel, M., Jonker, J.T., Schoones, J., Lamb, H., de Roos, A., Pijl, H., Smit, J.W.A., Meinders, A.E., Jazet, I.M., Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int. J. Endocrinol., 2012, 2012, 983814.
41. Solinas, G., Borén, J., Dulloo, A.G., De novo lipogenesis in metabolic homeostasis: more friend than foe?. Mol. Metab. 4 (2015), 367–377.
42. Sun, Z., Miller, R.A., Patel, R.T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M.J., Unterman, T.G., Shulman, G.I., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18 (2012), 934–942.
43. Sunny, N.E., Parks, E.J., Browning, J.D., Burgess, S.C., Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14 (2011), 804–810.
44. Titchenell, P.M., Chu, Q., Monks, B.R., Birnbaum, M.J., Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun., 6, 2015, 7078.
45. Titchenell, P.M., Quinn, W.J., Lu, M., Chu, Q., Lu, W., Li, C., Chen, H., Monks, B.R., Chen, J., Rabinowitz, J.D., Birnbaum, M.J., Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab. 23 (2016), 1154–1166.
46. Tripathy, S., Torres-Gonzalez, M., Jump, D.B., Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J. Lipid Res. 51 (2010), 2642–2654.
47. Wan, M., Leavens, K.F., Saleh, D., Easton, R.M., Guertin, D.A., Peterson, T.R., Kaestner, K.H., Sabatini, D.M., Birnbaum, M.J., Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 14 (2011), 516–527.
48. Williams, K.J., Argus, J.P., Zhu, Y., Wilks, M.Q., Marbois, B.N., York, A.G., Kidani, Y., Pourzia, A.L., Akhavan, D., Lisiero, D.N., et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 73 (2013), 2850–2862.
49. Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X.X., Pandey, S.K., Bhanot, S., Monia, B.P., Li, Y.X., Diehl, A.M., Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (2007), 1366–1374.
50. Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T., Niimi, T., Fujii, H., Okanoue, T., Yoshikawa, T., Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab. Invest. 90 (2010), 1169–1178.
51. Zhang, D., Liu, Z.-X., Choi, C.S., Tian, L., Kibbey, R., Dong, J., Cline, G.W., Wood, P.A., Shulman, G.I., Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc. Natl. Acad. Sci. USA 104 (2007), 17075–17080.